European Journal of Pharmacology, Journal Year: 2024, Volume and Issue: 969, P. 176452 - 176452
Published: Feb. 28, 2024
Language: Английский
European Journal of Pharmacology, Journal Year: 2024, Volume and Issue: 969, P. 176452 - 176452
Published: Feb. 28, 2024
Language: Английский
Journal of Bionic Engineering, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 7, 2025
Language: Английский
Citations
0International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125328 - 125328
Published: Feb. 1, 2025
Language: Английский
Citations
0Future Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 15
Published: Feb. 20, 2025
The advancement of targeted drug delivery systems has opened up a wide array opportunities in cancer therapy, leading to the exploration various strategies. Among these, use prodrugs stands out as particularly promising approach treatment, aimed at enhancing selectivity and effectiveness cytotoxic agents. In last few years, there been considerable progress area dimeric-based therapy. advantages presented by have significantly improved efficiency delivering anticancer drugs, characterized high loading capacity, advantageous pharmacokinetics, release that responds tumor stimuli. With respect importance dimerization field prodrug development, herein we review latest reports covering research dimeric prodrugs. We categorized article according reported also spent great deal attention on different types used linkers methods dissociation into free monomeric drugs. Readers will easily be able compare between using same drugs with or well cell lines studies.
Language: Английский
Citations
0Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown
Published: April 1, 2025
Small-molecule targeted drugs have become the mainstream cancer treatment due to their specific therapy. However, drug resistance inevitably happens patients. Herein, we propose "targeted conjugate (TDC)" concept design that enhance antitumor activity, reduce toxicity, and reverse resistance. Upon this idea, compounds Lapa-603 Lapa-604 were obtained by modifying Pt(II) units with Lapatinib's pharmacophore. Research has found can potently inhibit proliferation of tested cells multiple cell targeting EGFR protein causing severe DNA damage. More importantly, presented higher tumor growth inhibitory efficacy than Lapatinib, Cisplatin, or physical mixtures in both MDA-MB-231 BT474 xenograft models. Our research provided promise for development novel based on TDC effectively overcome stronger activity lower toxicity corresponding combination
Language: Английский
Citations
0International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 272, P. 132888 - 132888
Published: June 1, 2024
Language: Английский
Citations
4International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 299, P. 140204 - 140204
Published: Jan. 21, 2025
Language: Английский
Citations
0Advances in Continuous and Discrete Models, Journal Year: 2025, Volume and Issue: 2025(1)
Published: Jan. 17, 2025
Language: Английский
Citations
0Medical Oncology, Journal Year: 2025, Volume and Issue: 42(3)
Published: Feb. 3, 2025
Language: Английский
Citations
0Colloids and Surfaces B Biointerfaces, Journal Year: 2025, Volume and Issue: 250, P. 114563 - 114563
Published: Feb. 12, 2025
Language: Английский
Citations
0Biomaterials Advances, Journal Year: 2025, Volume and Issue: 171, P. 214235 - 214235
Published: Feb. 15, 2025
Language: Английский
Citations
0